Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031317 | 0.79 | LIPG (0.56) | LPLLIPG | |
| SCHEMBL1458500 | 0.77 | DGAT1 (0.53) | LPLLIPGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL257870 | 0.76 | LIPG (0.56) | LPLLIPG | |
| SCHEMBL8362996 | 0.75 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL29405082 | 0.74 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL432670 | 0.74 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL171814 | 0.73 | LPL (0.50) | LPLLIPGSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL22660887 | 0.72 | LPL (0.44) | LPLLIPGNPC1RAB9AALDH1A1 | |
| SCHEMBL4635750 | 0.71 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3388873 | 0.71 | L3MBTL1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480556-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036128-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070190-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, RTF2, HCCS | LPL 3435/4885LIPG 3788/4885NPC1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.